Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells

1 May 2016

Abstract excerpt

Resistance to available hormone therapies in prostate cancer has been associated with alternative splicing of androgen receptor (AR) and specifically, the expression of truncated and constitutively active AR variant 7 (AR-V7). The transcriptional activity of steroid receptors, including AR, is dependent on interactions with the HSP90 chaperone machinery, but it is unclear whether HSP90 modulates the activity or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heat shock proteins research
Share to Prostate Cancer Treatment and Research
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27197266
DOI: 10.1158/0008-5472.can-15-2186

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsPMID 27197266Read ↗

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.Semantic proximity Read ↗

Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancerSemantic proximity Read ↗

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerSemantic proximity Read ↗

AR Splicing Variants and Resistance to AR Targeting AgentsSemantic proximity Read ↗

<scp>Androgen receptor</scp> splice variant 7 in castration‐resistant prostate cancer: Clinical considerationsSemantic proximity Read ↗

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.Semantic proximity Read ↗

Decoding the androgen receptor splice variants.Semantic proximity Read ↗

Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.Semantic proximity Read ↗

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate CancerSemantic proximity Read ↗

Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.Semantic proximity Read ↗

A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancerSemantic proximity Read ↗

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.